


Product Name : ARCC-4
Cat. No. : PC-22554
CAS No. : 1973403-00-7
Molecular Formula : C₅₃H₅₆F₃N₇O₇S₂
Molecular Weight : 1024.18
Target : PROTAC
Solubility : 10 mM in DMSO



Biological Activity

ARCC-4 is a potent, selective enzalutamide-based von Hippel-Lindau (VHL)-recruiting androgen receptor (AR) degrader with DC50 of 5 nM in VCaP cells.

ARCC-4 is better at overcoming resistance in cellular models of castration-resistant prostate cancer (CRPC).

ARCC-4 is better than enzalutamide at inducing apoptosis and inhibiting proliferation of AR-amplified prostate cancer cells.

ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy, and maintains its potency to degrade AR and inhibit cell proliferation in a high androgen environment in which enzalutamide has no activity.

References

Salami J, et al. Commun Biol. 2018 Aug 2;1:100.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com